Literature DB >> 18829522

Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance.

Alain Vonlaufen1, Phoebe A Phillips, Zhihong Xu, David Goldstein, Romano C Pirola, Jeremy S Wilson, Minoti V Apte.   

Abstract

Pancreatic cancer--a tumor displaying a particularly abundant stromal reaction--is notorious for its poor prognosis. Recent studies, via newly developed orthotopic models, provide compelling evidence of an important role for pancreatic stellate cells (PSC) in pancreatic cancer progression. Characterization of the mechanisms mediating PSC-cancer interactions will lead to the development of much needed alternative therapeutic approaches to improve disease outcome.

Entities:  

Mesh:

Year:  2008        PMID: 18829522     DOI: 10.1158/0008-5472.CAN-08-1132

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  87 in total

1.  Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression.

Authors:  Matthew J Strouch; Eric C Cheon; Mohammad R Salabat; Seth B Krantz; Elias Gounaris; Laleh G Melstrom; Surabhi Dangi-Garimella; Edward Wang; Hidayatullah G Munshi; Khashayarsha Khazaie; David J Bentrem
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

2.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

3.  Antifibrotic Therapy Disrupts Stromal Barriers and Modulates the Immune Landscape in Pancreatic Ductal Adenocarcinoma.

Authors:  Kianna Y Elahi-Gedwillo; Marjorie Carlson; Jon Zettervall; Paolo P Provenzano
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

4.  Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.

Authors:  Min Shi; Dang-Hui Yu; Ying Chen; Chen-Yan Zhao; Jing Zhang; Qing-Hua Liu; Can-Rong Ni; Ming-Hua Zhu
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

Review 5.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 6.  Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer.

Authors:  Han Liu; Qingyong Ma; Qinhong Xu; Jianjun Lei; Xuqi Li; Zheng Wang; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.

Authors:  Daniel H Ahn; Andrew H Ko; Neal J Meropol; Tanios S Bekaii-Saab
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

8.  Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model.

Authors:  Tista Roy Chaudhuri; Ninfa L Straubinger; Rosemarie F Pitoniak; Bonnie L Hylander; Elizabeth A Repasky; Wen Wee Ma; Robert M Straubinger
Journal:  Mol Cancer Ther       Date:  2015-10-29       Impact factor: 6.261

9.  Stromal interactions as regulators of tumor growth and therapeutic response: A potential target for photodynamic therapy?

Authors:  Jonathan P Celli
Journal:  Isr J Chem       Date:  2012-07-24       Impact factor: 3.333

10.  Transcriptome profiles of carcinoma-in-situ and invasive non-small cell lung cancer as revealed by SAGE.

Authors:  Kim M Lonergan; Raj Chari; Bradley P Coe; Ian M Wilson; Ming-Sound Tsao; Raymond T Ng; Calum Macaulay; Stephen Lam; Wan L Lam
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.